Yesterday, I had an ask-all, tell-all interview with Dr. Fuhrman to open up some of the criticism he is facing lately and give him another platform to spread his message.2:31 How do you respond to criticism that you have simply modified your diet in order to have something specific to sell versus the other plant-based doctors who just advocate whole foods. Nuts and Seeds6:40 There is some controversy surrounding nuts and seeds in the diet. 6:58 Some people simply cannot lose weight while eating any nuts and seeds? If you're an addict you might need to have none to lose weight.11:12 Nuts and seeds should not be used for heart disease patients. 21:34 Benefits of nuts and seeds is from substitution of not eating meat24:09 Can you comment on Dr.Ornish adding in some nuts and seeds to his heart disease protocol? Were you involved with that?26:35 It's been said that you have weak research and draw improper conclusions.Even after you were told about a mistake in his weight loss study outcome, you continued to make a false claim. You have tried to cover up your mistakes. What is really going on?32:06 People question the way you speak, that you're a fast talker, and you're so blunt and direct. You make people uneasy. You use scare tactics and fear mongering to sell your products. Could you speak to these opinions?39:53 Does everyone have to take a DHA/EPA supplement?Since you do your own research and sell your own supplements, you are hard to trust. You shouldn't make money off supplements. It's a conflict of interest. You sell DHA/EPA but it's not necessary for everyone.Joan Sabat?(C). Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: evidence from epidemiologic studies.The American Journal of Clinical Nutrition, 1999;70(3):500s-503s. This review paper confirms the Adventist data on nuts and seeds and reduction of death, holds consistent for both vegan, vegetarian, and nonvegetarians.Since then these same results have been verified over and over again, especially in the Adventist Health study 2, published in 2018.REVIEW ARTICLESeidl SE, Santiago JA, Bilyk H, et al. The emerging role of nutrition in Parkinson's diseaseFront. Aging Neurosci., 07 March 2014 | https://doi.org/10.3389/fnagi.2014.00036(excerpt, there was more that Dr Fuhrman sent over, but description limits to 5000 characters)Omega-3 polyunsaturated fatty acids (PUFAs) appear to be neuroprotective for several neurodegenerative diseases (Bousquet et al., 2011a). There have been no studies in PD patients that address whether omega-3s are neuroprotective, however, one study showed that supplementation with omega-3 PUFA reduced depression in PD patients (Da Silva et al., 2008). Current research focuses specifically on the omega-3 fatty acid docosahexaenoic acid (DHA). DHA is an essential factor in brain growth and development (Horrocks and Yeo, 1999) and has anti-inflammatory potential due to its ability to inhibit cyclooxygenase-2 (Massaro et al., 2006). DHA protects neurons against cytotoxicity, inhibition of nitrogen oxide (NO) production, and calcium (Ca2+) influx. DHA also increases the activities of antioxidant enzymes glutathione peroxidase and glutathione reductase (Wang et al., 2003). Furthermore, DHA supplementation reduced apoptosis in dopaminergic cells (Ozsoy et al., 2011) and replaced omega-6-PUFAs in the brains of mice post-MPTP treatment (Bousquet et al., 2008). Short-term administration of DHA reduced levodopa-induced dyskinesias in parkinsonian primates by up to 40% (Samadi et al., 2006). Long-term administration of uridine and DHA increased the amount of neural phosphatides in synaptic membranes (Wurtman et al., 2006) and dendritic spines in rodents (Sakamoto et al., 2007). In addition, a reduction in parkinsonian behaviors and elevated dopamine (DA) levels in 6-OHDA rodents was observed after treatment with these supplements (Cansev et al., 2008). Further research on DHA intake in PD patients is needed to assess whether it is beneficial in slowing disease progression.The protective effects of DHA are mediated by a metabolic derivative known as neuroprotectin D1 (NPD1) (Bazan, 2009; Serhan and Petasis, 2011). NPD1 protects neurons against oxidative stress, inflammation, the disruption of the cytoskeleton, and from the activation of apoptotic signaling pathways. DHA may protect the brain by increasing glutathione reductase activity that results in decreased accumulation of oxidized proteins (Calon et al., 2004; Wu et al., 2004), lipid peroxide and reactive oxygen species (ROS) (Hashimoto et al., 2005). DHA also inactivates caspase activation signaling pathways (Calon et al., 2005)...The precursor to DHA, eicosapentaenoic acid (EPA) is neuroprotective in experimental models of PD (Song et al., 2009; Meng et al., 2010; Taepavarapruk and Song, 2010; Luchtman et al., 2012). In in vitro models of PD, EPA attenuated an MPP+-induced ...